N4 Pharma PLC
LSE:N4P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
N4 Pharma PLC
Revenue
N4 Pharma PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
N4 Pharma PLC
LSE:N4P
|
Revenue
£7.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Revenue
£32.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Revenue
$58.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$3.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Revenue
£57.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
3%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Revenue
£178.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
N4 Pharma PLC
Glance View
N4 Pharma Plc is a pharmaceutical company, which engages in the reformulation of existing drugs and vaccines. The company is headquartered in Derby, Derbyshire and currently employs 5 full-time employees. The company went IPO on 2005-06-07. The firm is engaged in engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company is focused on developing a delivery system for vaccines and cancer treatments using its silica nanoparticle delivery system called Nuvec. Nuvec is a non-viral adjuvant delivery system that has the potential to revolutionize vaccines and cancer treatments. The company is focused on development and commercialization of medicines via its delivery system.
See Also
What is N4 Pharma PLC's Revenue?
Revenue
7.1k
GBP
Based on the financial report for Jun 30, 2025, N4 Pharma PLC's Revenue amounts to 7.1k GBP.
What is N4 Pharma PLC's Revenue growth rate?
Revenue CAGR 1Y
20%
Over the last year, the Revenue growth was 20%.
